J&J’s venture arm is betting on neuromodulation
Johnson & Johnson doesn't have an internal neuromodulation program, but its corporate venture arm is active in this therapy modality.
Johnson & Johnson doesn't have an internal neuromodulation program, but its corporate venture arm is active in this therapy modality.
Following in the vein of Five Hour Energy, FAST is purveying a series of "liquid shots" that treat common maladies like colds, pain, heartburn and hangovers. J&J's venture arm invested in a $24 million round.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Throughout the year Lake Whillans, with the help of MedCity News, has explored two key issues for healthcare investors and entrepreneurs: trust and reliability. We’ve helped bring to light some harrowing war stories of partnerships gone bad. We’ve also asked healthcare leaders in the trenches about the best ways to operate in the modern healthcare […]